(For other news from the Reuters Health Summit, click on
http://www.reuters.com/summit/Health08?pid=500)
NEW YORK, Nov 18 (Reuters) - Amgen's head of
oncology research said on Tuesday that one of the company's
experimental drugs now in mid-stage trials has big potential to
better starve tumors of their blood supply when used with
standard medicines.
"It's new, we're ahead of the field and it has potential in
a number of tumor types," Glenn Begley said at the Reuters
Health Summit, calling the AMG 386 drug one of Amgen's most
promising oncology products.
"What we're trying to achieve is not incremental," Begley
said. "We want to make a difference; we want to have
substantial benefit" in further controlling cancer.
(Reporting by Ransdell Pierson)
Content Provided by
Reuters Reuters is the largest international news agency -- providing professionals around the world with stories that move the markets.
- 
- 
- 
Welcome,
Guest!
News
